中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

485 records (took 0.023 seconds)

    BRANCHED POLYETHYLENE GLYCOL FOR LINKING POLYMER RESIDUES TO ANTIBODIES
    15.
    发明申请
    BRANCHED POLYETHYLENE GLYCOL FOR LINKING POLYMER RESIDUES TO ANTIBODIES 审中-公开
    用于将聚合物残留物连接到抗体的分支聚乙烯甘油

    公开(公告)号：WO2005061005A3

    公开(公告)日：2005-11-03

    申请号：PCT/GB2004005246

    申请日：2004-12-14

    Applicant: CELLTECH R&D LTD ,  NORMAN TIMOTHY JOHN

    Inventor： NORMAN TIMOTHY JOHN

    IPC: A61K47/48

    CPC classification number: A61K47/60

    Abstract: Branched molecular scaffolds are provided which are capable of linking two polymer residues (derived, for example, from polyethylene glycol) to two, three or four residues derived from biologically active molecules (e.g. from whole antibodies or from functionally active fragments or derivatives thereof), the latter being attached to the scaffold by means of hydrolytically stable linkages.

    Abstract translation: 提供支链分子支架，其能够将两个聚合物残基（衍生自例如聚乙二醇）与衍生自生物活性分子（例如来自全部抗体或其功能活性片段或衍生物）的两个，三个或四个残基连接， 后者通过水解稳定的键连接到支架上。

    USE OF DUDULIN2 FOR THE TREATMENT OR PROPHYLAXIS OF LUNG CANCER
    16.
    发明申请
    USE OF DUDULIN2 FOR THE TREATMENT OR PROPHYLAXIS OF LUNG CANCER 审中-公开
    使用DUDULIN2治疗或预防肺癌

    公开(公告)号：WO2005049066A3

    公开(公告)日：2005-07-14

    申请号：PCT/GB2004004847

    申请日：2004-11-16

    Applicant: CELLTECH R&D LTD ,  TERRETT JONATHAN ALEXANDER

    Inventor： TERRETT JONATHAN ALEXANDER

    IPC: A61K38/17 ,  G01N33/50 ,  G01N33/574 ,  A61P35/00

    CPC classification number: A61K38/1709 ,  G01N33/57423 ,  G01N2500/04

    Abstract: The present invention relates to new uses of dudulin2 in the diagnosis, screening, treatment and prophylaxis of lung cancer. The invention also provides compositions comprising dudulin2, especially vaccines, and agents which interact with or modulate the expression or activity of dudulin2 or which modulate the expression of the nucleic acid which codes for dudulin2.

    Abstract translation: 本发明涉及dudulin2在诊断，筛选，治疗和预防肺癌中的新用途。 本发明还提供包含dudulin2，特别是疫苗的组合物，以及与dudulin2的表达或活性相互作用或调节其调节凋亡蛋白2的核酸表达的试剂。

    PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS
    19.
    发明申请
    PROPANOIC ACID DERIVATIVES AS INTEGRIN INHIBITORS 审中-公开
    作为整合抑制剂的丙酸衍生物

    公开(公告)号：WO0144194A3

    公开(公告)日：2001-12-13

    申请号：PCT/GB0004831

    申请日：2000-12-15

    Applicant: CELLTECH R&D LTD ,  ALEXANDER RIKKI PETER ,  LANGHAM BARRY JOHN ,  REUBERSON JAMES THOMAS ,  TROWN EMMA LOUISE ,  WARRELLOW GRAHAM JOHN

    Inventor： ALEXANDER RIKKI PETER ,  LANGHAM BARRY JOHN ,  REUBERSON JAMES THOMAS ,  TROWN EMMA LOUISE ,  WARRELLOW GRAHAM JOHN

    IPC: C07D213/74 ,  C07D213/89 ,  C07D401/12 ,  A61K31/44 ,  A61K31/4439 ,  A61K31/444 ,  A61P29/00 ,  A61P35/00

    CPC classification number: C07D213/74 ,  C07D213/89 ,  C07D401/12

    Abstract: Propanoic acid derivatives of formula (1) are described: Ar-X -Ar -Z-R; in which Ar is a nitrogen base containing group; X is a linker atom or group; Ar is an optionally substituted pyridine or pyridine-N-oxide; Z is a group -CH(R )CH2- [in which R is R or Alk R , R is a hydrogen atom or an optionally substituted aliphatic, cycloaliphatic heteroaliphatic, heterocycloaliphatic, aromatic or heteroaromatic group and Alk is an optionally substituted C1-3alkylene chain], -C(R )(R )-CH(R )- [in which R and R together with the carbon atoms to which they are attached form a C3-7cycloalkyl group] or -C(R )=CH-; R is a carboxylic acid (-CO2H) or a derivative or biostere thereof; and the salts, solvates, hydrates and N-oxides thereof. The compounds are able to inhibit the binding of integrins to their ligands and are of use in the prophylaxis and treatment of immune or inflammatory disorders.

    Abstract translation: 式（1）的丙酸衍生物描述为：Ar-X 1 -Ar 1 -Z-R; 其中Ar是含氮碱基团; X 1是接头原子或基团; Ar 1是任选取代的吡啶或吡啶-N-氧化物; Z为基团-CH（R 13）CH 2 - [其中R 13为R 13a或Alk 1a R 13a，R 13a为氢原子或任选取代的脂族基团， 脂环族杂脂族基，杂环脂族基，芳族或杂芳族基团且Alk 1a为任选取代的C 1-3亚烷基链]，-C（R 12a）（R 13）-CH（R 12b） - [ R 12a和R 12b与它们所连接的碳原子一起形成C 3-7环烷基]或-C（R 13）= CH-; R是羧酸（-CO 2 H）或其衍生物或生物等排物; 及其盐，溶剂化物，水合物和N-氧化物。 该化合物能够抑制整联蛋白与其配体的结合，并且可用于预防和治疗免疫或炎性疾病。

    VACCINES AND ANTIBODIES AGAINST LTK FOR THERAPY OF CANCERS.
    20.
    发明申请
    VACCINES AND ANTIBODIES AGAINST LTK FOR THERAPY OF CANCERS. 审中-公开
    疫苗和反对LTK治疗癌症的抗体。

    公开(公告)号：WO2005105143A3

    公开(公告)日：2006-04-27

    申请号：PCT/GB2005001698

    申请日：2005-05-04

    Applicant: CELLTECH R&D LTD ,  STAMPS ALASDAIR CRAIG

    Inventor： STAMPS ALASDAIR CRAIG

    IPC: C07K16/28 ,  A61K39/00 ,  A61K39/395 ,  A61P35/00

    CPC classification number: A61K39/0011

    Abstract: The present invention relates to new uses of LTK in the diagnosis, screening, treatment and prophylaxis of ovarian and lung cancer. The invention also provides compositions comprising LTK, including vaccines, antibodies that are immunospecific for LTK and agents which interact with or modulate the expression or activity of LTK or which modulate the expression of the nucleic acid which codes for LTK.

    Abstract translation: 本发明涉及LTK在诊断，筛选，治疗和预防卵巢癌和肺癌中的新用途。 本发明还提供包含LTK的组合物，包括疫苗，对LTK具有免疫特异性的抗体和与LTK的表达或活性相互作用或调节LTK的表达或活性或调节编码LTK的核酸表达的试剂。

Patent Agency Ranking